Our partnering strategy is to combine our company strengths with the expertise of oncology and orphan companies to maximize the commercial opportunities of our novel products.
Our goal is to leverage our expertise in the biology of cellular apoptosis (cell death) for multiple oncology and orphan applications and partner with companies with extensive clinical and commercial expertise in our areas of focus.
Select partnering with leading companies in our focus areas is critical to the success of our company and our products. We seek to identify and enter into alliances, collaborations in our target indications for which our partners have extensive established experience in clinical development and commercialization.
In September 2009, we entered into a partnership with Zhejiang Hisun Pharmaceutical Co. Ltd. for our early-stage oncology product CBLB612 for China only.
We are open to inquiries regarding partnerships for our drugs in development.